Xcelom Limited

Xcelom has been exclusive licensed by CUHK to provide an Non-Invasive Prenatal Technology (NIPT) service called "safeT21express". safeT21express is a test that analyses such circulating cell-free DNA molecules with next-generation DNA sequencing technologies, and performs bioinformatics analysis. Genetic information from the unborn child can be obtained, which could include the screening results for: - Down syndrome (T21) - Edwards syndrome (T18) - Patau syndrome (T13) - Sex chromosome aneuploidies: 45, X0 (Turner syndrome) - Sex chromosome aneuploidies: 47, XXY (Klinefelter syndrome) - Sex chromosome aneuploidies: 47, XXX (Triple X) - Sex chromosome aneuploidies: 47, XYY (Jacob syndrome) - Microdeletions analysis related to 1p36 deletion syndrome - Microdeletions analysis related to 2q33.1 deletion syndrome - Microdeletions analysis related to Angelman syndrome - Microdeletions analysis related to Cri-du-Chat syndrome - Microdeletions analysis related to 22q11 deletion syndrome (include DiGeorge syndrome) - Microdeletions analysis related to Langer-Giedion syndrome - Microdeletions analysis related to Prader-Willi syndrome Looking ahead, Xcelom will continue to use Hong Kong as its base to market its NIPT solution to Asia and the rest of the world.

Website

http://www.xcelom.com

External link for Xcelom Limited

Industry

Biotechnology Research

Company size

51-200 employees

Headquarters

Hong Kong, Hong Kong

Type

Privately Held